NEWARK, N.J., Jan. 6, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced it has received correspondence from KHA Solutions Group following a December 2010 meeting in Kentucky.
KHA Solutions Group, a for-profit entity and a wholly owned subsidiary of Kentucky Hospital Association, indicated that pending further investigation into BioNeutral and its products, BioNeutral may be selected as a partner in KHA Solutions Group's Affinity Partner Program. KHA Solutions Group exists primarily to support KHA financially, by generating non-dues revenue and is governed by a board of KHA member hospital executives. At board direction, the Affinity Partner Program seeks best-in-class companies which provide a valuable product or service to member hospitals, and forms strategic partnerships with those companies for mutual benefit.
Referring to the value of a potential partnership as "multi-faceted", KHA Solutions group outlined the additional due diligence that will be necessary before a partnership may be entered, including Ygiene's regulatory approval, negotiation of acceptable financial terms and board approval. Upon acceptance into the program, a marketing plan would be collaboratively developed.
"We are encouraged by our ongoing interactions with KHA Solutions Group," said Dr. Andy Kielbania, PhD, Chief Scientist and Director at BioNeutral, "and are looking forward to partnering with local Kentucky organizations to provide the platform for a new level of safety and effectiveness for hospitals and patients throughout the state."
For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been submitted to the EPA for approval for sale in the United States and has already been approved for sale in Germany and is permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
|SOURCE BioNeutral Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved